Home Newsfeeds DA Davidson Maintains Neutral on Criteo, Raises Price Target to $39

DA Davidson Maintains Neutral on Criteo, Raises Price Target to $39

DA Davidson analyst Tom White maintains Criteo (NASDAQ:CRTO) with a Neutral and raises the price target from $29 to $39.

byBenzinga Newsdesk

February 10, 2023

1 minute read

DA Davidson analyst Tom White maintains Criteo (NASDAQ:CRTO) with a Neutral and raises the price target from $29 to $39.

Longeveron Announces $4M Registered Direct Offering Of 2,424,243 Shares Of Common Stock At a Price Of $1.65/Share, Priced At-the-Market Under Nasdaq Rules

By Benzinga Newsdesk

October 12, 8:08 AM

Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart

LGVN

Ra Medical Systems Announces The Presentation Of Clinical Data At The European Heart Rhythm Association Congress

By Benzinga Newsdesk

January 23, 7:51 AM

Ra Medical Systems, Inc. (NYSE:RMED) (Ra Medical), a medical device and technology company focused on cardiac electrophysiology, announces that four abstracts with clinical data supporting its VIVO technology have been

RMED

Analyst Ratings

Where HashiCorp Stands With Analysts

By Benzinga Insights

August 30, 10:00 AM

Analysts have provided the following ratings for HashiCorp (NASDAQ:HCP) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

HCP

Exelixis Q2 EPS $0.28 Beats $0.19 Estimate, Sales $419.43M Beat $390.91M Estimate

By Benzinga Newsdesk

August 9, 4:40 PM

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.19 by 47.37 percent. This is a 24.32 percent decrease over earnings of $0.37 per share from the same

EXEL

DA Davidson Maintains Neutral on Criteo, Raises Price Target to $39

Related Posts

Longeveron Announces $4M Registered Direct Offering Of 2,424,243 Shares Of Common Stock At a Price Of $1.65/Share, Priced At-the-Market Under Nasdaq Rules

Ra Medical Systems Announces The Presentation Of Clinical Data At The European Heart Rhythm Association Congress

Where HashiCorp Stands With Analysts

Exelixis Q2 EPS $0.28 Beats $0.19 Estimate, Sales $419.43M Beat $390.91M Estimate